SESN2/sestrin 2 induction-mediated autophagy and inhibitory effect of isorhapontigenin (ISO) on human bladder cancers

Isorhapontigenin (ISO) is a new derivative of stilbene isolated from the Chinese herb Gnetum cleistostachyum. Our recent studies have revealed that ISO treatment at doses ranging from 20 to 80 μM triggers Apoptosis in multiple human Cancer cell lines. In the present study, we evaluated the potential effect of ISO on Autophagy induction. We found that ISO treatment at sublethal doses induced Autophagy effectively in human bladder Cancer cells, which contributed to the inhibition of anchorage-independent growth of Cancer cells. In addition, our studies revealed that ISO-mediated Autophagy induction occurred in a SESN2 (sestrin 2)-dependent and BECN1 (Beclin 1, Autophagy related)-independent manner. Furthermore, we identified that ISO treatment induced SESN2 expression via a MAPK8/JNK1 (mitogen-activated protein kinase 8)/JUN-dependent mechanism, in which ISO triggered MAPK8-dependent JUN activation and facilitated the binding of JUN to a consensus AP-1 binding site in the SESN2 promoter region, thereby led to a significant transcriptional induction of SESN2. Importantly, we found that SESN2 expression was dramatically downregulated or even lost in human bladder Cancer tissues as compared to their paired adjacent normal tissues. Collectively, our results demonstrate that ISO treatment induces Autophagy and inhibits bladder Cancer growth through MAPK8-JUN-dependent transcriptional induction of SESN2, which provides a novel mechanistic insight into understanding the inhibitory effect of ISO on bladder cancers and suggests that ISO might act as a promising preventive and/or therapeutic drug against human bladder Cancer.